Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou Duration: 15 mins Various reorts suggest the preferiantial use of Ankinra ver tocilizumab in  CAR T-cell associated toxicities

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 25 mins Hyperbilirubinemia occurs frequently after allogeneic stem cell transplantation. Causes include primary liver damage and endothelial complications as major contributors. Here, we have investigated the impact of early bilirubinemia (EB) on posttransplant outcomes. Maximum total...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou Duration: 20 mins The outcome of refractory/relapsed (R/R) acute leukemias is still dismal and their treatment represents an unmet clinical need. However, allogeneic transplantation (allo-HSCT) remains the only potentially curative approach...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou Duration: 20 mins Pre-harvest autologous blood collection from bone marrow (BM) donors is performed to meet potential post-operative transfusion needs. This study examines the impact of autologous blood transfusion on BM...

Ομιλητής: Vincent van Dam Συμμετέχοντες: Καθ. Α. Σπυριδωνίδης, Λίγκα Μαρία, Τσοκάνας Δημήτρης, Σαγιαδινού Ελευθερία, Ζαχαριουδάκη Βασιλική, Κεφάλα Διονυσία Στα πλαίσια του Μεταπτυχιακού Προγραμματος  «Cell and Gene Therapies: from bench to bedside and Good Manufacturing Practices» πραγματοποιήθηκε τηλεδιάσκεψη με τίτλο "Elements of a QA...

Presenter: Evangelia Arampatzi, CRA Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas, Sagiadinou E., Panagi Z. Today, on 16 March 2022 training about study protocol "AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter, Study to Evaluate Efficacy, Safety and Tolerability of Axatilimab at 3...

Presenter: Gakis George Participants: Prof Spyridonidis, Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou An abstact on behalf of 28th SCHMS congress, presented by Medical student George Gakis. Chimeric antigen receptor (CAR) T-cells have revolutionized the standards of care for patients with hematologic malignancies....

A study on behalf of the Acute Leukemia Working Party of the EBMT, presented by Prof. Spyridonidis Is 8- instead of 12-Gray sufficient for acute lymphoblastic ,leukemia patients transplanted in first complete remission? Total body irradiation (TBI) continues to be an important part...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A., Panagi Z. Post-transplant cyclophosphamide (PTCY) is increasingly used for allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from an HLA-matched unrelated donor (MUD) as an alternative to the standard anti-thymocyte globulin...

Presenters: Dr Wendy Stock, Dr Scott Howard, Dr Stephen Hunger, Dr Dan Douer Participants: Prof. Spryridonidis See the on-demand webcast of ASH2021 titled “Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience” On ASH2021 symposium the treatment of adult patients with Acute Lymphoblastic Leukemia with pegaspargase was discussed, as well...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A., Panagi Z. Patients with DLBCL primary refractory or relapsed ≤ 12 mo after first-line (1L) therapy may have poor outcomes with SOC, including salvage CT and ASCT, which underscores a...

Presenter: Stephen Kim (Manager QA Site Qualification) Participants: Dr Liga, Dr Triantafyllou, Christopoulou A., Sagiadinou E., Kefala D., Parastatidou S., Tzourtzou A., Maniati S. Την Τετάρτη 02 Φεβρουαρίου 2022 πραγματοποιήθηκε εκπαίδευση του προσωπικού που συμμετέχει στη Λευκαφαίρεση από την εταιρεία Kite Pharma. H εκπαίδευση...

Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A. Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with myelodysplastic syndrome (MDS). Although less intense therapies are being used more often in AML, the dichotomy between...

Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas  Due to fast spreading of SARS-CoV-2 a panel of experts of EBMT recommends the following guidelines for transplant units, recipients, and donors of hematopoietic cells. These guidelines will be updated when new information is...

Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Christopoulou A., Sagiadinou E. Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible...

In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion,...

In the coronavirus disease 19 (COVID-19) pandemic era, the number of haploidentical hematopoietic cell transplantations (HCTs) with peripheral blood (PB) grafts increased significantly compared with HCTs with bone marrow (BM) grafts, which may be associated with adverse outcomes. We compared outcomes of HCT in...

The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. In this international, phase 3 trial, patients with large B-cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy...